Business
Press Release Mar 15 2024
Aurobindo Pharma Limited has informed the Exchange regarding a press release dated March 15, 2024, titled "Press Release that is being issued by the Company in connection with announcement by CuraTeQ Biologics Private Limited, a wholly owned subsidiary of the Company, the successful Phase 1 clinical study outcome of their BP11 product (a biosimilar to Xolair).".
About this update from Aurobindo Pharma Ltd
[{"type":"text","content":" Aurobindo Pharma Limited has informed the Exchange regarding a press release dated March 15, 2024, titled \"Press Release that is being issued by the Company in connection with announcement by CuraTeQ Biologics Private Limited, a wholly owned subsidiary of the Company, the successful Phase 1 clinical study outcome of their BP11 product (a biosimilar to Xolair).\". View Attachment","length":534,"tagName":"div"}]